Clinical trials have shown that patients’ breast tumor pathologic complete response (pCR) to NAC was significantly higher in those with triple-negative tumors and HER2-positive tumors (47.9% and 50.2%, respectively) than in those with hormone receptor positive, HER2-negative tumors (15.5%, p < 0.0001) [8]. This evidence concerns the gene ERBB2 and breast neoplasm.